Infinitas Capital

Einwert is a pioneering European hybrid appraiser that is transforming real estate valuation by integrating digital technology with a focus on environmental, social, and governance (ESG) compliance. The company has developed a real estate value management platform designed to enhance the capabilities of appraisers while providing unmatched market transparency and sustainability insights. By replacing traditional manual processes with intelligent parameter determination, Einwert enables clients to obtain accurate and sustainability-driven valuations. This innovative approach empowers real estate investors to make informed, future-oriented decisions that support their business growth and contribute to a more sustainable real estate market.

Wonder Brands is a Latin American startup that focuses on partnering with successful digital brands to enhance their growth potential. The company specializes in establishing strategic alliances with these brands, offering significant investments to boost working capital, marketing efforts, and equipment. In addition to financial support, Wonder Brands adds value through expertise in technology, digital marketing, supply chain management, administration, and finance. By leveraging data science and analytics, the company helps its partners respond effectively to consumer needs and diversify their product offerings and target audiences.

Operator of a clinical-stage biopharmaceutical company intended to develop therapies for Alzheimer's disease. The company engages in developing a drug that is an orally administered small molecule treatment that enhances neurotransmission in the brain and improves both cognition and independent global function, enabling medical practitioners to use neurotransmission and improve both cognition and independent global function.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

Opeartor of a digital platform intended to convert real estate assets into cash assets. The company provides partial real estate sales of the property places customers at the center of all our considerations and efforts and relies on tailor-made, individual solutions, enabling customers to keep all decision-making options and buy back the part sold at any time or sell the entire property.

Exporo AG is a Hamburg-based company that operates an online real estate crowdfunding platform in Germany. Founded in 2014 by Simon Brunke, Björn Maronde, Tim Bütecke, and Julian Oertzen, Exporo connects private investors with real estate developers seeking capital. The platform offers an accessible and transparent way for individuals to invest in real estate projects that were traditionally available only to institutional investors. By allowing low minimum investments, Exporo enables retail investors to diversify their portfolios while benefiting from attractive interest rates. The company has grown significantly and now employs over 120 people, continuously evolving to meet the needs of both investors and developers in the changing financial landscape.

Einwert is a pioneering European hybrid appraiser that is transforming real estate valuation by integrating digital technology with a focus on environmental, social, and governance (ESG) compliance. The company has developed a real estate value management platform designed to enhance the capabilities of appraisers while providing unmatched market transparency and sustainability insights. By replacing traditional manual processes with intelligent parameter determination, Einwert enables clients to obtain accurate and sustainability-driven valuations. This innovative approach empowers real estate investors to make informed, future-oriented decisions that support their business growth and contribute to a more sustainable real estate market.

AMZSCALE is an eCommerce agency specializing in Amazon fulfillment services. The company is staffed by a team of experienced professionals who have practical knowledge gained from building and managing successful Amazon brands, some of which they have sold. AMZSCALE offers a range of services designed to assist third-party businesses in optimizing their operations on the Amazon platform. These services include detailed research and sourcing, operational excellence, sales infrastructure development, brand optimization, and strategies for scaling operations. By leveraging their expertise, AMZSCALE aims to help clients achieve significant growth in the competitive eCommerce landscape.

FORME, founded in 2020 and based in Los Angeles, California, offers an integrated home fitness platform that focuses on sports and fitness instruction. The company provides interactive wellness and strength training sessions, allowing customers to engage in personalized workouts from the comfort of their homes. In addition to fitness training, FORME’s health coaching services include guidance on nutrition, recovery, sleep, and various lifestyle aspects. Revenue is generated through the sale of connected fitness products, membership fees, and personal training services, positioning FORME as a comprehensive solution for individuals seeking to enhance their fitness and overall well-being.

Storypod is a company focused on fostering a love of learning in children through an interactive, screen-free audio platform. Designed for children, the platform incorporates RFID-enabled yarn figurines, read-along audiobooks, and trivia cards to create an engaging educational experience. This innovative system allows kids to enjoy classic stories, music, and games while promoting independent learning. By leveraging data insights, Storypod aims to provide stage-based content that supports parents, grandparents, and educators in nurturing smart, healthy, and resilient children.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Customuse is a company that develops virtual apparel design software, allowing users to create wearable augmented reality outfits. The platform features an intuitive interface and offers unique templates for designing outfits for virtual avatars. This enables users to bring their product ideas to life and effectively market their designs in popular games and augmented reality spaces. Through Customuse, creators can sell their designs while engaging with their audience on social media, thereby promoting their brands and expanding their reach within the digital environment.

Olsam Group is a technology-driven commerce company that specializes in acquiring and operating leading Amazon third-party and direct-to-consumer eCommerce brands on a global scale. The company conducts thorough due diligence on potential acquisitions, structures equitable cash deals, and transfers assets such as website domains and software tools to its ownership. Once acquired, Olsam focuses on scaling these brands through strategic capital investment and supply chain expertise. This approach allows business owners the flexibility to fully exit their operations or remain involved as desired.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

NextMarkets GmbH, founded in 2014 and based in Cologne, Germany, offers a user-friendly web and mobile application tailored for private investors engaging in capital markets. The platform allows users to trade a wide range of financial instruments, including contracts for difference (CFDs) on equities, foreign exchange, bonds, and commodities. Recognizing that a significant majority of private investors struggle in the stock market due to behavioral economic factors, NextMarkets aims to empower its users by providing educational resources, training, and strategies that enhance their trading experience. The company's mission is to promote a more informed and sustainable approach to investing, enabling users to better understand market dynamics and make informed trading decisions.

Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing aging-related diseases. The company specializes in regulating cellular homeostasis, which involves restoring balance within cells to eliminate toxic accumulations. By targeting the cellular systems responsible for maintaining cellular health, Booster Therapeutics aims to create drug modalities that can prevent and treat various diseases associated with aging.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.